Loading
institutionsInstitution
Maria Skłodowska-Curie National Research Institute of Oncology
Poland's national cancer institute, founded on Marie Curie's initiative in 1932, with branches in Gliwice and Kraków and the national cancer registry.
Also called: NIO-PIBCentrum OnkologiiInstytut im. Marii Skłodowskiej-CurieMaria Sklodowska- Curie National Research Institute of Oncology
· 1 more · Fewer names
Maria Sklodowska-Curie National Research Institute of Oncology
Overview
The Radium Institute opened in Warsaw in 1932 at the initiative of Maria Skłodowska-Curie, who donated a gram of radium, and today the National Research Institute of Oncology is Poland's largest cancer centre and national reference institution, with branches in Gliwice and Kraków. It hosts the Polish National Cancer Registry, coordinates the national cancer strategy and cooperative trials, and its Kraków branch treats patients with protons at the Bronowice Cyclotron Centre. Piotr Rutkowski's sarcoma and melanoma department is a European reference and contributes to ESMO guidelines, and the institute has large radiotherapy, brachytherapy, surgical and haematology departments. It runs early-phase trials and the national precision oncology programme.
Location
Warsaw, PL
Type
cancer center
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#95 · 40 points (0 Newsweek + 0 NCI + 40 from 20 linked objects) · ranking
- National cancer registry and strategy
- Sarcoma and melanoma
- Radiotherapy and brachytherapy
- Proton therapy (Kraków branch)
- Haematology
Andrzej Kawecki
Deputy Director for Clinical Affairs
Radiation oncologyHead and neck cancer
Radiation oncologist specialising in head and neck cancer who oversees clinical affairs at Poland's National Research Institute of Oncology.
Beata Jagielska
Director
Clinical oncologyChemotherapyInternal medicine
Clinical oncologist who directs Poland's national cancer institute, the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw.
Michał Mikula
Deputy Director for Scientific Affairs
Cancer geneticsColorectal cancerTranslational research
Molecular geneticist who leads the scientific programme of Poland's National Research Institute of Oncology.
Piotr Rutkowski
Surgical oncologist and head of soft tissue, bone sarcoma and melanoma, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw
MelanomaSarcoma and GISTDermatofibrosarcoma protuberans
Polish surgical oncologist who led the pooled EORTC and SWOG trials showing that imatinib shrinks dermatofibrosarcoma protuberans, a rare skin sarcoma driven by a PDGFB fusion.
Similar pages
- InstitutionIstanbul University Institute of Oncology
Shares Brachytherapy, Most of the world has almost no cancer care, IMRT / IGRT (modern external beam), HR-positive / HER2-negative breast cancer.
- InstitutionEuropean Society for Radiotherapy and Oncology
Shares EORTC, European Society for Medical Oncology (ESMO), Brachytherapy, Proton therapy.
- InstitutionLausanne University Hospital (CHUV) / Ludwig Institute Lausanne
Shares EORTC, European Society for Medical Oncology (ESMO), Melanoma, Immune checkpoint inhibitors.
- InstitutionMasaryk Memorial Cancer Institute
Shares Brachytherapy, IMRT / IGRT (modern external beam), Melanoma, HR-positive / HER2-negative breast cancer.
- InstitutionInstitute of Oncology Ljubljana
Shares Brachytherapy, IMRT / IGRT (modern external beam), Melanoma, HR-positive / HER2-negative breast cancer.
- InstitutionHacettepe University Cancer Institute
Shares Brachytherapy, Most of the world has almost no cancer care, IMRT / IGRT (modern external beam), HR-positive / HER2-negative breast cancer.
- IdeaBlended finance and a low-cost linac to close the global radiotherapy gap
Shares Brachytherapy, Most of the world has almost no cancer care, IMRT / IGRT (modern external beam), HR-positive / HER2-negative breast cancer.
- IdeaA Global Fund for cancer care in low- and middle-income countries
Shares Brachytherapy, Most of the world has almost no cancer care, IMRT / IGRT (modern external beam), HR-positive / HER2-negative breast cancer.